<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446053</url>
  </required_header>
  <id_info>
    <org_study_id>ITB-101_1b</org_study_id>
    <nct_id>NCT03446053</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Dose-Escalating Phase 1b Study to Evaluate the Safety, PK, PD and Immunogenicity of N-Rephasin® SAL200 After Continuous IV Infusion in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intron Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intron Biotechnology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of N-Rephasin®&#xD;
      SAL200 following single and multiple ascending doses in healthy male volunteers after&#xD;
      continuous intravenous infusion over 60 minutes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection&#xD;
           or a placebo administered by a 60-min intravenous infusion. Within each group, 8&#xD;
           subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by&#xD;
           multiple ascending dose of 3, 6, 9, and 12 mg/kg/day. The clinical trial will be&#xD;
           performed in sequence from the lowest level, and the progress of the next dose level&#xD;
           will be determined based on the safety results in the previous dose level.&#xD;
&#xD;
        -  Examinations by interview, physical examinations, and screening tests such as clinical&#xD;
           laboratory tests and allergenicity will be conducted in volunteers within 4 weeks&#xD;
           (-28~-2d) from the previous day ot this clinical trial (-1d) to select subjects who are&#xD;
           judged eligible for the study.&#xD;
&#xD;
        -  Eligible subjects will be called in the afternoon (-1d) to examine the allergenicity in&#xD;
           the clinical center of Seoul National Unviersity Hospital.&#xD;
&#xD;
        -  Allergen-free subjects will be hospitalized on -1d and assigned with each subject&#xD;
           number. All subjects are advised to fast from 10:00 p.m. overnight to the next morning,&#xD;
           except drinking water. In the morning (09:00 a.m.) on 1d, subjects in each group will be&#xD;
           given N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous&#xD;
           infusion, After that, the clinical trial will be conducted according to the designated&#xD;
           schedule.&#xD;
&#xD;
        -  All subjects receiving at least one dose will undergo a post-study visit test after a&#xD;
           certain period of time. Immunogenicity testing will be performed until approximately 50&#xD;
           days after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Actual">February 7, 2019</completion_date>
  <primary_completion_date type="Actual">February 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability Evaluation</measure>
    <time_frame>Up to 50D (±2D)</time_frame>
    <description>Monitoring of adverse events (AEs) for Safety and Tolerability Evaluation</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation [Cmax (µg/mL)]</measure>
    <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
    <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Up to 2hours</time_frame>
    <description>Ex vivo antibacterial activity was assessed by bactericidal effects of the serum specimens collected from the trials were compared with calibration samples range of 0.05 to 1.0 μg/mL N-Rephasin®SAL200.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity Evaluation</measure>
    <time_frame>Up to 50D (±2D)</time_frame>
    <description>Anti-drug antibody titer was assessed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation [AUClast, AUCinf (µg*h/mL)]</measure>
    <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
    <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation [Tmax, T1/2, MRTinf (h)]</measure>
    <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
    <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation [Vd (L)]</measure>
    <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
    <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Evaluation [CL (L/h)]</measure>
    <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
    <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Anti-Bacterial Agents</condition>
  <condition>Methicillin-Resistant Staphylococcus Aureus</condition>
  <condition>Methicillin-Sensitive Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>N-Rephasin® SAL200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INT200-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>N-Rephasin® SAL200</intervention_name>
    <description>continuous intravenous infusion over 60 minutes</description>
    <arm_group_label>N-Rephasin® SAL200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>INT200-Placebo</intervention_name>
    <description>Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes</description>
    <arm_group_label>INT200-Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects aged between 20 and 45 years at screening&#xD;
&#xD;
          -  Those whose body weight is between 50kg and 90kg, and BMI is between 18.0 and 27.0&#xD;
&#xD;
          -  Subjects who have fully understood this clinical trial via detailed explanation, are&#xD;
             willing to voluntarily participate in this study, and agree to give written informed&#xD;
             consent and to follow all of trial-related rules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have clinically significant liver, kidney, nervous system, endocrine system,&#xD;
             respiratory system, hemato-oncology, cardiovascular system, mental diseases or past&#xD;
             history.&#xD;
&#xD;
          -  Those who have been diagnosed or suspected infectious disease within 30 days prior to&#xD;
             the first dose of study medication&#xD;
&#xD;
          -  Those who have history of hypersensitivity to drugs containing N-Rephasin® SAL200 or&#xD;
             other drugs (aspirin and antibiotics)&#xD;
&#xD;
          -  Those who have taken other drugs containing N-Rephasin® SAL200.&#xD;
&#xD;
          -  Those who are antibody-positive to N-Rephasin® SAL200&#xD;
&#xD;
          -  Those who have SBP &lt;90mmHg or DBP &lt;50mmHg (otherwise SBP &gt; 150mmHg or DBP &gt; 100mmHg)&#xD;
             in vital signs, when measured after a 3-minute rest in sitting position.&#xD;
&#xD;
          -  Those who have medical history of drug abuse or positive to urine drug screening&#xD;
&#xD;
          -  Has taken any prescription drugs or herbal medicines within 14 days prior to first&#xD;
             dose of study medication; otherwise, has taken over-the-counter drugs or vitamins&#xD;
             within 7 days prior to the first dose of study medication (However, if other&#xD;
             conditions are appropriate upon judgment of the investigator, the subject may&#xD;
             participate in this study.)&#xD;
&#xD;
          -  Those who has taken other study medications within 3 months prior to the study&#xD;
             medication&#xD;
&#xD;
          -  Those who have donated whole blood within 2 months prior to the first dose of study&#xD;
             medication or apheresis within 1 month, or received blood transfusion within 1 months&#xD;
             prior to the first dose of study medication&#xD;
&#xD;
          -  Those who smoke cigarettes or are found to be nicotine metabolite-positive in&#xD;
             urinalysis&#xD;
&#xD;
          -  Those who cannot continuously abstain from drinking alcohol (exceeding 21 units/week,&#xD;
             1 unit = 10g of pure alcohol) or smoking cigarettes during hospitalization&#xD;
&#xD;
          -  Those who are judged ineligible for the clinical study by the investigator due to&#xD;
             other reasons, including the results of clinical laboratory tests&#xD;
&#xD;
          -  Those who do not agree to use medically accepted contraceptive measures for 60 days&#xD;
             after the first dose of study medication, or those who are unwilling to report the&#xD;
             partner's pregnancy until 90 days after the first dose of study medication&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Jin Jang, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001432619</url>
    <description>Seung-Ho Han et al., Monitoring of Methicillin-Resistant Staphylococcus aureus in Nasal Swabs Obtained fron Dental Clinic Healthcare Providers and Medical Environments Nurses. Int J Oral Biology. 2010;35:7-12</description>
  </link>
  <link>
    <url>https://www.semanticscholar.org/paper/Analysis-of-Economic-Outcomes-of-Staphylococcus-Park-Chae/f848ff1bc9cf6e346dbbc24bd4b4bf669dd70b43</url>
    <description>Eun Ja Park et al., Analysis of Economic Outcome of Methicillin-Resistant Staphylococcus aureus(MRSA) Bacteremia Using Retrospective Case-Control Study, Kor. J. Clin. Pharm 2007;17:59-64</description>
  </link>
  <link>
    <url>https://ir.ymlib.yonsei.ac.kr/handle/22282913/147505</url>
    <description>Hyuk Min Lee, Dong Eun Yong, Kyungwon Lee., Antimicrobial Resistance of Clinically Important Bacteria Isolated from 12 Hospitals in Korea in 2004 . Korean Journal of Clinical Microbiology 2005;8(1):66-73</description>
  </link>
  <link>
    <url>https://www.microbiologyresearch.org/content/journal/ijsem/10.1099/00207713-38-2-168</url>
    <description>Frency J, Brun Y, Bes M, Meugnier H, Grimont F, Grimon PAD, Newi C, Fleurette J. Staphylococcus lugdunensis sp. and Staphylococcus schleiferi sp. novel two species from human clinical specimens. Int Syst Bacteriol. 1998;38:168-172</description>
  </link>
  <reference>
    <citation>Etienne J, Fleurette J, Ninet JF, Favet P, Gruer LD. Staphylococcal endocarditis after dental extraction. Lancet. 1986 Aug 30;2(8505):511-2.</citation>
    <PMID>2875256</PMID>
  </reference>
  <reference>
    <citation>Kundsin RB. Documentation of airborne infection during surgery. Ann N Y Acad Sci. 1980;353:255-61.</citation>
    <PMID>6939390</PMID>
  </reference>
  <reference>
    <citation>van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012 Apr;25(2):362-86. doi: 10.1128/CMR.05022-11. Review.</citation>
    <PMID>22491776</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 4, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <results_first_submitted>June 16, 2021</results_first_submitted>
  <results_first_submitted_qc>September 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2021</results_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methicillin-Resistant Staphylococcus Aureus</keyword>
  <keyword>Methicillin-Sensitive Staphylococcus Aureus</keyword>
  <keyword>N-Rephasin SAL200</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03446053/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT03446053/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment was conducted in a single center (SEOUL NATIONAL UNIVERSITY HOSPITAL) from Feb. 2018 to Dec. 2018.</recruitment_details>
      <pre_assignment_details>59 subjects were screened and 33 subjects met inclusion criteria and were randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Single Dose Study</title>
          <description>INT200-Placebo, single dose, IP administration: 1d 0h</description>
        </group>
        <group group_id="P2">
          <title>N-Rephasin® SAL200 6mg/kg (Single Dose)</title>
          <description>Sigle dose group N-Rephasin® SAL200 6mg/kg (single dose)&#xD;
Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
        <group group_id="P3">
          <title>Placebo , Multiple Dose Study</title>
          <description>INT200-Placebo, multiple dose, IP administration: 1d 0h, 2d 0h, 2d 12h, 3d 0h, 3d 12h and 4d 0h</description>
        </group>
        <group group_id="P4">
          <title>N-Rephasin® SAL200 1.5 mg/kg (3mg/kg/d) , Multi Dose</title>
          <description>multi dose study Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
        <group group_id="P5">
          <title>N-Rephasin® SAL200 3mg/kg (6mg/kg/d), Multi Dose</title>
          <description>Multi dose study Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
        <group group_id="P6">
          <title>N-Rephasin® SAL200 4.5mg/kg (9mg/kg/d), Multi Dose</title>
          <description>Multi dose study Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized Set</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PK/PD Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>INT200-Placebo (Single Dose Study + Multi Dose Study)</title>
          <description>Saline&#xD;
INT200-Placebo: Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes</description>
        </group>
        <group group_id="B2">
          <title>N-Rephasin® SAL200 6mg/kg (Single Dose)</title>
          <description>Sigle dose N-Rephasin® SAL200 6mg/kg (single dose)&#xD;
Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
        <group group_id="B3">
          <title>N-Rephasin® SAL200 1.5 mg/kg (3mg/kg/d), Multi Dose</title>
          <description>Multi dose Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
        <group group_id="B4">
          <title>N-Rephasin® SAL200 3mg/kg (6mg/kg/d), Multi Dose</title>
          <description>Multi dose Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
        <group group_id="B5">
          <title>N-Rephasin® SAL200 4.5mg/kg (9mg/kg/d), Multi Dose</title>
          <description>Multi dose Experimental: N-Rephasin® SAL200&#xD;
Active ingredient : SAL200 1ml (SAL-1 18 mg/mL) Manufacturer: BINEX Co., Ltd. (whole process contracted) Transparent and colorless vial filled with colorless clear liquid injection&#xD;
continuous intravenous infusion over 60 minutes&#xD;
Healthy Volunteers who were met eligibility criteria.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="5.6"/>
                    <measurement group_id="B2" value="28.5" spread="6.0"/>
                    <measurement group_id="B3" value="33.5" spread="6.2"/>
                    <measurement group_id="B4" value="31.3" spread="5.8"/>
                    <measurement group_id="B5" value="29.2" spread="4.9"/>
                    <measurement group_id="B6" value="30.2" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.2" spread="8.8"/>
                    <measurement group_id="B2" value="73.1" spread="5.5"/>
                    <measurement group_id="B3" value="70.3" spread="9.1"/>
                    <measurement group_id="B4" value="74.2" spread="5.9"/>
                    <measurement group_id="B5" value="69.1" spread="8.7"/>
                    <measurement group_id="B6" value="73.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178.1" spread="6.2"/>
                    <measurement group_id="B2" value="175.0" spread="4.6"/>
                    <measurement group_id="B3" value="174.0" spread="3.6"/>
                    <measurement group_id="B4" value="174.5" spread="2.5"/>
                    <measurement group_id="B5" value="174.7" spread="4.9"/>
                    <measurement group_id="B6" value="175.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability Evaluation</title>
        <description>Monitoring of adverse events (AEs) for Safety and Tolerability Evaluation</description>
        <time_frame>Up to 50D (±2D)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo, Single Dose Study</title>
            <description>INT200-Placebo, single dose, IP administration: 1d 0h</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 (6mg/kg), Single Dose Study</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 6 mg/kg, single dose, IP administration: 1d 0h</description>
          </group>
          <group group_id="O3">
            <title>Placebo , Multiple Dose Study</title>
            <description>INT200-Placebo, multiple dose, IP administration: 1d 0h, 2d 0h, 2d 12h, 3d 0h, 3d 12h and 4d 0h</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 (1.5 mg/kg), Multiple Dose Study</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 1.5 mg/kg (3 mg/kg/day), Multiple dose, IP administration: 1d 0h, 2d 0h, 2d 12h, 3d 0h, 3d 12h and 4d 0h</description>
          </group>
          <group group_id="O5">
            <title>N-Rephasin® SAL200 (3 mg/kg), Multiple Dose Study</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 3 mg (6 mg/kg/day) , Multiple dose, IP administration: 1d 0h, 2d 0h, 2d 12h, 3d 0h, 3d 12h and 4d 0h</description>
          </group>
          <group group_id="O6">
            <title>N-Rephasin® SAL200 (4.5 mg/kg), Multiple Dose Study</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 4.5 mg (9 mg/kg/day), Multiple dose, IP administration: 1d 0h, 2d 0h, 2d 12h, 3d 0h, 3d 12h and 4d 0h</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Evaluation</title>
          <description>Monitoring of adverse events (AEs) for Safety and Tolerability Evaluation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No. of Subjects with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of Subjects with Drug-Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No. of Subjects with Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation [Cmax (µg/mL)]</title>
        <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
        <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 (6mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 6 mg/kg, single dose</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 (1.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 1.5 mg/kg (3 mg/kg/day), single IV administration of N-Rephasin® SAL200</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 (3 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 3 mg (6 mg/kg/day) , single IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 (4.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 4.5 mg (9 mg/kg/day), single IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation [Cmax (µg/mL)]</title>
          <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="3.91"/>
                    <measurement group_id="O2" value="1.24" spread="0.509"/>
                    <measurement group_id="O3" value="4.93" spread="1.08"/>
                    <measurement group_id="O4" value="10.8" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacodynamic Evaluation</title>
        <description>Ex vivo antibacterial activity was assessed by bactericidal effects of the serum specimens collected from the trials were compared with calibration samples range of 0.05 to 1.0 μg/mL N-Rephasin®SAL200.</description>
        <time_frame>Up to 2hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>6 mg/kg</title>
            <description>single IV administration of N Rephasin® SAL200 IV administration.</description>
          </group>
          <group group_id="O2">
            <title>1.5 mg/kg</title>
            <description>after single IV administration of N Rephasin® SAL200 IV administration.</description>
          </group>
          <group group_id="O3">
            <title>3 mg/kg</title>
            <description>single IV administration of N Rephasin® SAL200 IV administration.</description>
          </group>
          <group group_id="O4">
            <title>4.5 mg/kg</title>
            <description>single IV administration of N Rephasin® SAL200 IV administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamic Evaluation</title>
          <description>Ex vivo antibacterial activity was assessed by bactericidal effects of the serum specimens collected from the trials were compared with calibration samples range of 0.05 to 1.0 μg/mL N-Rephasin®SAL200.</description>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1.5h Mean concentration of bactericidal activity (μg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.24"/>
                    <measurement group_id="O2" value="0.14" spread="0.20"/>
                    <measurement group_id="O3" value="0.22" spread="0.10"/>
                    <measurement group_id="O4" value="0.20" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2h Mean concentration of bactericidal activity (μg/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.07"/>
                    <measurement group_id="O2" value="0.02" spread="0.03"/>
                    <measurement group_id="O3" value="0.07" spread="0.07"/>
                    <measurement group_id="O4" value="0.08" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunogenicity Evaluation</title>
        <description>Anti-drug antibody titer was assessed.</description>
        <time_frame>Up to 50D (±2D)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Single Dose Study + Multi Dose Study)</title>
            <description>INT200-Placebo (single dose study (2 participants) + multi dose study (6 participants) = total 8 participants)</description>
          </group>
          <group group_id="O2">
            <title>SAL200 N-Rephasin® SAL200 (6mg/kg) (Single Dose Study)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL) , 6 mg/kg (Single dose study)</description>
          </group>
          <group group_id="O3">
            <title>SAL200 1.5 mg/kg (3 mg/kg/d) (Multi Dose Study)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 1.5 mg/kg (3 mg/kg/day) (Multi dose study)</description>
          </group>
          <group group_id="O4">
            <title>SAL200 3 mg/kg (6 mg/kg/d) (Multi Dose Study)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 3 mg (6 mg/kg/day) (Multi dose study)</description>
          </group>
          <group group_id="O5">
            <title>SAL200 4.5 mg/kg (9 mg/kg/d) (Multi Dose Study)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 4.5 mg (9 mg/kg/day) (Multi dose study)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Evaluation</title>
          <description>Anti-drug antibody titer was assessed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA present at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA negative at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive post baseline (regardless of baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADA positive post baseline (baseline negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation [AUClast, AUCinf (µg*h/mL)]</title>
        <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
        <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 (6mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 6 mg/kg, single dose</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 (1.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 1.5 mg/kg (3 mg/kg/day), single IV administration of N-Rephasin® SAL200</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 (3 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 3 mg (6 mg/kg/day) , single IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 (4.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 4.5 mg (9 mg/kg/day), single IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation [AUClast, AUCinf (µg*h/mL)]</title>
          <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
          <units>µg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC last</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="7.04"/>
                    <measurement group_id="O2" value="1.10" spread="0.503"/>
                    <measurement group_id="O3" value="5.65" spread="1.33"/>
                    <measurement group_id="O4" value="11.3" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC inf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="7.05"/>
                    <measurement group_id="O2" value="1.14" spread="0.519"/>
                    <measurement group_id="O3" value="5.70" spread="1.35"/>
                    <measurement group_id="O4" value="11.8" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation [Tmax, T1/2, MRTinf (h)]</title>
        <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200</description>
        <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 (6mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 6 mg/kg, single dose</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 (1.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 1.5 mg/kg (3 mg/kg/day), single IV administration of N-Rephasin® SAL200</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 (3 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 3 mg (6 mg/kg/day) , single IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 (4.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 4.5 mg (9 mg/kg/day), single IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation [Tmax, T1/2, MRTinf (h)]</title>
          <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.00"/>
                    <measurement group_id="O2" value="1.00" spread="1.00"/>
                    <measurement group_id="O3" value="1.00" spread="1.00"/>
                    <measurement group_id="O4" value="1.00" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2 (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="3.40"/>
                    <measurement group_id="O2" value="0.386" spread="0.0820"/>
                    <measurement group_id="O3" value="0.726" spread="0.214"/>
                    <measurement group_id="O4" value="1.16" spread="0.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MRTinf (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.314"/>
                    <measurement group_id="O2" value="0.656" spread="0.0760"/>
                    <measurement group_id="O3" value="0.782" spread="0.596"/>
                    <measurement group_id="O4" value="0.760" spread="0.0651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation [Vd (L)]</title>
        <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
        <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 (6mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 6 mg/kg, single dose</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 (1.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 1.5 mg/kg (3 mg/kg/day), single IV administration of N-Rephasin® SAL200</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 (3 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 3 mg (6 mg/kg/day) , single IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 (4.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 4.5 mg (9 mg/kg/day), single IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation [Vd (L)]</title>
          <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" spread="89.5"/>
                    <measurement group_id="O2" value="55.6" spread="13.0"/>
                    <measurement group_id="O3" value="41.3" spread="9.82"/>
                    <measurement group_id="O4" value="46.4" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacokinetic Evaluation [CL (L/h)]</title>
        <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
        <time_frame>Single administration: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 hours post-dose Multiple administration: the above timepoints and 25, 36, 48, 49, 60, 72, 72.25, 72.5, 72.75, 73, 73.5, 74, 75, 76, 77, 78, 80, 82, 84, 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-Rephasin® SAL200 (6mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 6 mg/kg, single dose</description>
          </group>
          <group group_id="O2">
            <title>N-Rephasin® SAL200 (1.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 1.5 mg/kg (3 mg/kg/day), single IV administration of N-Rephasin® SAL200</description>
          </group>
          <group group_id="O3">
            <title>N-Rephasin® SAL200 (3 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 3 mg (6 mg/kg/day) , single IV administration</description>
          </group>
          <group group_id="O4">
            <title>N-Rephasin® SAL200 (4.5 mg/kg)</title>
            <description>SAL200 1 ml (SAL-1 18 mg/mL), 4.5 mg (9 mg/kg/day), single IV administration</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Evaluation [CL (L/h)]</title>
          <description>Blood sampling for PK evaluation was performed at the following time points. Summary of PK parameters after single IV administration of N-Rephasin® SAL200.</description>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="5.63"/>
                    <measurement group_id="O2" value="107" spread="47.1"/>
                    <measurement group_id="O3" value="40.3" spread="5.89"/>
                    <measurement group_id="O4" value="27.4" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 50 Days after randomization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo, Single Dose Study</title>
          <description>INT200-Placebo (N=2),single dose study</description>
        </group>
        <group group_id="E2">
          <title>N-Rephasin® SAL200 (6mg/kg), Single Dose Study</title>
          <description>N-Rephasin® SAL200 (6mg/kg), (N=6),single dose study</description>
        </group>
        <group group_id="E3">
          <title>Placebo , Multiple Dose Study</title>
          <description>INT200-Placebo (N=6),multiple dose study</description>
        </group>
        <group group_id="E4">
          <title>N-Rephasin® SAL200 (1.5 mg/kg), Multiple Dose Study</title>
          <description>N-Rephasin® SAL200 (1.5mg/kg), (N=6),multiple dose study</description>
        </group>
        <group group_id="E5">
          <title>N-Rephasin® SAL200 (3 mg/kg), Multiple Dose Study</title>
          <description>N-Rephasin® SAL200 (3mg/kg), (N=6),multiple dose study</description>
        </group>
        <group group_id="E6">
          <title>N-Rephasin® SAL200 (4.5 mg/kg), Multiple Dose Study</title>
          <description>N-Rephasin® SAL200 (4.5mg/kg), (N=6),multiple dose study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (ver. 20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site induration</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion site warmth</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jun SooYoun, Ph.D. / Executive Director/ Principal researcher</name_or_title>
      <organization>Institute of iNtRON Biotechnology</organization>
      <phone>+82-31-739-5332</phone>
      <email>jsy@intron.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

